Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.61 |
| ▸ | CNR2 | P34972 | 11/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606201 | 0.99 | CNR1 (0.60) | CNR1CNR2LMNACYP1A2CYP3A4 | |
| SCHEMBL4605679 | 0.99 | CNR1 (0.60) | CNR1CNR2LMNACYP1A2CYP3A4 | |
| SCHEMBL4607836 | 0.95 | CNR1 (0.67) | CNR1CNR2CYP2C9GPR55 | |
| SCHEMBL4606282 | 0.94 | CNR1 (0.66) | CNR1CNR2CYP2C9GPR55 | |
| SCHEMBL4607208 | 0.94 | CNR1 (0.66) | CNR1CNR2CYP2C9GPR55 | |
| Hydrochloric Acid SCHEMBL5591135 | 0.93 | CNR1 (0.65) | CNR1CNR2CYP2C9GPR55 | |
| SCHEMBL4605063 | 0.91 | CNR1 (0.75) | CNR1CNR2LMNACYP1A2CYP3A4 | |
| SCHEMBL4606429 | 0.91 | CNR1 (0.60) | CNR1CNR2 | |
| SCHEMBL5591642 | 0.91 | CNR2 (0.60) | CNR1CNR2 | |
| SCHEMBL4607388 | 0.91 | CNR1 (0.60) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1946777-A1 | Substituted pyrazoline for preventing weight gain | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | claimed |
| EP-1946778-A1 | Active substance combination for the treatment of diabetes | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | claimed |
| EP-1743887-A1 | Thiocarbonyl-substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
| EP-1946777-A1 | Substituted pyrazoline for preventing weight gain | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | disclosed |
| EP-1946778-A1 | Active substance combination for the treatment of diabetes | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007009688-A1 | THIOCARBONYL-SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | disclosed |
| EP-1743887-A1 | Thiocarbonyl-substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |